1 nges may be implicated in the development of xerosis.

2 n in human immunodeficiency virus-associated xerosis.

3 skin diseases, such as atopic dermatitis and xerosis.

4 ution and/or hair depigmentation (18 [44%]), xerosis (8 [20%]), scrotal erythema/ulceration (6 [15%])

5                              Corynebacterium xerosis, a constituent of the ocular flora, contains lar

6 onic inflammatory phenotype characterized by xerosis and pruritic eczematous lesions; dermal infiltra

7 atures of human atopic dermatitis, including xerosis, conjunctivitis, inflammatory skin lesions, Stap

8  (psoriasiform eczema, 30.6%; eczema, 23.5%; xerosis cutis, 10.6%; palmoplantar pustulosis, 5.3%; pso

9                                              Xerosis, drug reactions, and neuropathy should be consid

10       More than 50% of elderly patients have xerosis (dry skin).

11 oth treatment groups developed cheilitis and xerosis during treatment.

12 that are widely used to treat the pathologic xerosis/eczema seen in moderately aged humans.

13 s afflicted by inflammatory skin diseases or xerosis/eczema that could be triggered or exacerbated by

14                                       Severe xerosis occurs in approximately 20% of human immunodefic

15 n of human immunodeficiency virus-associated xerosis patients (upper arm, n = 12; upper leg, n = 11)

16 sent results show that amoebae exposed to C. xerosis produce increased amounts of MIP133 and more sev

17 r receptor antagonists: papulopustular rash, xerosis, pruritus as well as hair, nail, and mucosal cha

18                                              Xerosis treatment should be included in the initial ther